Search results for " therapeutic"
Article
Detecting Protein Aggregates and Evaluating their Immunogenicity
Protein aggregation can occur during all stages of the lifetime of a protein therapeutic, including expression, refolding, purification, sterilization, shipping, storage, and delivery processes (1). T…
Article
Single-Domain Antibodies for Brain Targeting
sdAbs have been forged into multivalent and multispecific therapeutics, or targeting moieties, that are able to shuttle their linked therapeutic cargo (i.e., drugs, nanoparticles, toxins, enzymes, and…
Article
Maximum Output Starts with Optimized Upstream Processing
Innovation in process analytical technologies (PAT) is similarly driven by the need to boost both the productivity and therapeutic value of each bioprocess, according to Vanek.
Shortening developm…
Article
New Therapies Present Scaling Challenges
By Feliza Mirasol
The approval of emerging biologic-based therapeutics—such as cell and gene therapies—presents challenges and decisions for drug companies looking to increase the manu…
Article
ADC Development Robust Despite Lackluster Performance
Optimism in the pipeline
Despite the promise of ADCs as an alternative therapeutic for cancers, response rates to these drugs in clinical trials have been typically low, and in addition, toxicity …
Article
Patenting Prospects for Cell-Based Therapies
The history of biomedical advances over the past 50 years has focused predominantly of increasing complexity, from small-molecule therapeutics to antibodies, cytokines, blood-clotting factors, and pro…
Article
Antibody Production in Microbial Hosts
Therapeutic mAbs and their derivatives—such as antibody fragments (Fab), single-chain Fv (scFv), and diabodies—represent the fastest-growing class of approved therapeutic proteins because of their hig…
Article
Applications of Surface Plasmon Resonance for Detection of Bispecific Antibody Activity
Advanced antibody engineering has resulted in the ability to manufacture new recombinant bispecific antibodies suitable for therapeutic use. FDA has approved a bispecific antibody—Amgen’s Blincyto (bl…
Article
Witnessing Major Growth in Next-Generation Antibodies
Many therapeutic targets
Oncology continues to be a key focus for next-generation antibody therapies, but Catalent is also seeing an interest in new modalities, such as conjugates, for other indic…
Article
HT Multi-Product Liquid Chromatography for Characterization of Monoclonal Antibodies
Monoclonal antibodies (MAbs) are an important class of therapeutic proteins in biotechnology and have been developed to treat a variety of indications to fill significant unmet medical needs.1 MAbs ge…